MétaCan
Menu
Back to cohort

Cabazitaxel in docetaxel-pretreated metastatic castration resistant prostate cancer (mCRPC): Canadian experience.

2013· article· en· W2968566719 on OpenAlexaffabout
Srikala S. Sridhar, Eric Winquist, Stacey Hubay, Hazem Assi, Scott R. Berry, John A. Stewart, Éric Lévesque, Nathalie Aucoin, Piotr Czaykowski, Fred Saad

Bibliographic record

VenueJournal of Clinical Oncology · 2013
Typearticle
Languageen
FieldMedicine
TopicCancer Treatment and Pharmacology
Canadian institutionsCancerCare ManitobaUniversité de MontréalUniversité LavalSanofi (Canada)Sunnybrook Health Science CentreUniversity of TorontoMoncton HospitalGrand River HospitalLondon Health Sciences CentrePrincess Margaret Cancer Centre
Fundersnot available
KeywordsMedicineDocetaxelCabazitaxelProstate cancerAdverse effectInternal medicineNeutropeniaFebrile neutropeniaPrednisoneSurgeryCancerChemotherapyAndrogen deprivation therapy

Abstract

fetched live from OpenAlex

e16082 Background: Cabazitaxel/prednisone (CbzP) improves survival in docetaxel resistant mCRPC. Canadian investigators collected safety, QoL and efficacy data in patients (pts) from a global Expanded Access Program. Methods: Following progression on or after docetaxel, all pts received cabazitaxel 25 mg/m² IV q3wkly and prednisone 10 mg daily. Safety and QoL were collected at baseline and at each cycle. Adverse events were graded according to NCI CTCAE v 4.0. Present pain intensity (PPI) and analgesic scores were assessed using the McGill-Melzack questionnaire. QoL was assessed using FACT-P and EQ 5D-3L. PSA was done at the investigator's discretion at each cycle and at the end of treatment. Results: 61 pts were enrolled at 9 centers. Median age was 65 (18% ≥ 75); 92% were ECOG 0/1; 89% had bone metastases and 21% had visceral metastases. Pts had a median of 9 cycles (median cumulative dose 675 mg/m2) of prior docetaxel, and 38% had progressed on or within 3 months of it. Notably 26 pts (43%) had also received and progressed on prior Abiraterone Acetate (AA) given before (5pts), or after docetaxel (21 pts). Half the patients (51%) received >6 cycles of CbzP. Median relative dose intensity was 99%. At cycle 1, 31% received prophylactic G-CSF. Main grade 3+ toxicities were anemia 9.8%, diarrhea 8.2%, fatigue 8.2% and febrile neutropenia 6.6%. Peripheral neuropathy was uncommon (4.9% ; no grade 3+). There was 1 treatment related death (1.6%) due to abdominal sepsis. Compared to baseline, PPI scores improved despite stable analgesic use and were significant at cycles 2, 4, 9 (p<0.05). The FACT-P prostate specific questions showed significant improvements in the first 4 cycles (p<0.05). On the EQ-5D-3L the percentage of patients reporting “no problem” for the pain domain by the last cycle increased. The PSA response rate (≥50% decrease) was 48.7% in 39 evaluable pts and was similar in AA pretreated and non-pretreated pts (47.1% and 50.0% respectively). Conclusions: In routine clinical practice, CbzP treatment was clinically manageable and toxicities were similar to the TROPIC study. PPI and QoL data support a palliative benefit of CbzP. PSA response rate was 48.7% and similar in AA pretreated and non-pretreated pts.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.668
Threshold uncertainty score0.668

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.001
Science and technology studies0.0010.000
Scholarly communication0.0010.000
Open science0.0010.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0040.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.163
GPT teacher head0.516
Teacher spread0.352 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2013
Admission routes2
Has abstractyes

Explore more

Same venueJournal of Clinical OncologySame topicCancer Treatment and PharmacologyFrench-language works237,207